Investigate Novel Therapeutic Interventions and Testing Strategies for Neurological Disorders Including to Treat, Modify and Prevent the Development of Epilepsy (U24 Clinical Trial Not Allowed)
ID: 360649Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$4M - $4M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360649
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for research aimed at investigating novel therapeutic interventions and testing strategies for neurological disorders, specifically targeting the treatment, modification, and prevention of epilepsy. This initiative encourages applicants to explore various intervention modalities and develop human-focused testing approaches, with a particular emphasis on preclinical therapy testing and model development. The total estimated program funding is $6.2 million, with individual awards ranging from $3.5 million to $4 million, and the application process is expected to open with a synopsis posted by December 19, 2025, closing on February 20, 2026. Interested applicants can reach out to Dr. Brian Klein at brian.klein@nih.gov or (301) 496-0981 for further information.

    Point(s) of Contact
    Brian Klein, PhD
    (301) 496-0981
    brian.klein@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for clinical studies aimed at advancing next-generation devices for recording and modulation in the human central nervous system, under the BRAIN Initiative. This initiative seeks to support small clinical trials that provide critical data necessary for the development of devices intended to treat central nervous system disorders, particularly those requiring an Investigational Device Exemption (IDE) from the FDA. The funding is crucial for enhancing neurotechnology and improving treatment outcomes, with NIH planning to allocate approximately $10 million annually for 5 to 7 awards, each with a maximum budget of $1.5 million per year for up to five years. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by September 28, 2026.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required), aimed at supporting multi-center clinical trials focused on neurological emergencies such as status epilepticus and traumatic brain injury. This initiative encourages collaboration with the NIH SIREN Clinical Coordinating Center to ensure efficient trial implementation, while applicants are expected to provide rigorous preclinical data and compelling rationales for their proposed interventions. The funding opportunity operates under a phased mechanism, with UG3 for planning and UH3 for execution, reflecting a commitment to enhance clinical research in emergency care. Interested applicants can find more information and application guidelines at the provided link, with a submission deadline of March 6, 2026, and no cost-sharing or matching requirements.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)." This initiative aims to support the characterization and efficacy studies of neurotherapeutic agents intended for treating neurological disorders, with a focus on conducting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate the biological activity of proposed therapeutic agents. The program emphasizes the importance of rigorous experimental design, collaboration, and the inclusion of diverse perspectives in research teams, aligning with NIH's mission to translate research discoveries into effective therapies. Interested applicants can apply for funding up to $499,000 per year for a total project duration not exceeding three years, with the application deadline set for October 20, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-225.html.
    Research Program Award (R35 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Research Program Award (R35 Clinical Trial Optional) aimed at providing long-term support and flexibility for Program Directors (PDs) and Principal Investigators (PIs) in the field of neurological research. This grant, which does not require cost sharing or matching, is designed to alleviate the administrative burdens associated with managing multiple grant applications, allowing researchers to focus on their scientific endeavors and mentorship roles. The funding, with an award ceiling of $750,000 and a floor of $350,000, is intended to foster innovative research that aligns with the mission of the National Institute of Neurological Disorders and Stroke (NINDS). Interested applicants can reach out to Alisa Schaefer at nindsr35@ninds.nih.gov for further information, with the estimated synopsis posting date set for April 15, 2026, and a projected award date of March 1, 2027.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE)" aimed at developing and validating model systems for neurotherapeutic discovery. This initiative encourages proposals for animal models or ex vivo systems that accurately replicate the characteristics of specific neurological or neuromuscular disorders, with the goal of enhancing the translational relevance of these models to improve drug development processes. The program utilizes a phased award mechanism (R61/R33) and requires collaboration with clinical experts, along with a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research. The total funding available is $750,000 over three years, with a maximum of $499,000 in direct costs per year. Key submission dates begin with the earliest application due date of January 18, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Forecast for NIH Blueprint and BRAIN Initiative ACTION Potential Program (F99/K00 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to announce a funding opportunity titled "Forecast for NIH Blueprint and BRAIN Initiative ACTION Potential Program (F99/K00 Clinical Trial Not Allowed)" aimed at supporting neuroscience graduate students. This initiative, under the NIH Blueprint for Neuroscience Research and the BRAIN Initiative, will provide a two-phase F99/K00 award designed to facilitate the completion of doctoral dissertations and assist in the transition to postdoctoral positions in neuroscience research. The program is crucial for developing the next generation of independent neuroscience researchers, emphasizing the importance of collaboration and project responsiveness. Interested applicants are encouraged to prepare in advance, as applications will not be solicited until the official announcement, which is expected to be published on November 3, 2025, with a closing date for submissions anticipated on March 20, 2026. For further inquiries, potential applicants can contact Dr. Lauren Ullrich at the National Institute of Neurological Disorders and Stroke via email at nindsotwd@ninds.nih.gov or by phone at 301-451-7964.
    BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System," aimed at advancing neuroscience research through innovative technology development. This initiative seeks applications for the creation of new hardware, software, or molecular constructs that address challenges in recording and modulating neural cells and circuits, with a focus on high-risk projects that could lead to transformative outcomes in understanding dynamic signaling within the central nervous system. The program allocates an estimated $10 million annually for 15-20 awards, emphasizing collaboration across scientific domains and encouraging participation from diverse institutions, particularly those supporting early-career researchers and underserved populations. Interested applicants should note that the application submission deadlines begin on May 2, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)" aimed at soliciting applications for research on exploratory and efficacy clinical trials that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS). This initiative will focus on evaluating various interventions, including drugs, biologics, devices, and therapies related to surgical, behavioral, and rehabilitation approaches. The opportunity is particularly significant for researchers with expertise in neurological disorders, as it encourages the development of meaningful collaborations and responsive projects in this critical health area. Interested applicants can reach out to Jeremy Brown, MD, via email at ExploratoryEfficacyTrials@ninds.nih.gov for further information, with the estimated synopsis posting date set for November 12, 2025, and applications expected to close by February 10, 2026.